OverviewSuggest Edit

Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics products. It focuses on oncology and hematology, cardiovascular, inflammation, bone health, and neuroscience diseases. Its major brands include:

TypePublic
Founded1980
HQThousand Oaks, CA, US
Websiteamgen.com
Employee Ratings4.1
Overall CultureF

Latest Updates

Employees (est.) (Dec 2020)24,300(+4%)
Job Openings1,026
Revenue (FY, 2020)$25.4 B(+9%)
Share Price (Sept 2021)$216
Cybersecurity ratingBMore

Key People/Management at Amgen

Robert A. Bradway

Robert A. Bradway

Chairman and Chief Executive Officer
Victoria H. Blatter

Victoria H. Blatter

Senior Vice President, U.S. Government Affairs
Judy Gawlik Brown

Judy Gawlik Brown

Senior Vice President, Corporate Affairs
Raymond Deshaies

Raymond Deshaies

Senior Vice President, Global Research
Murdo Gordon

Murdo Gordon

Executive Vice President, Global Commercial Operations
Jonathan Graham

Jonathan Graham

Executive Vice President, General Counsel and Secretary
Show more

Amgen Office Locations

Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 58 other locations
Thousand Oaks, CA, US (HQ)
1 Amgen Center Dr
Cambridge, MA, US
360 Binney St
Louisville, KY, US
12000 Plantside Dr
South San Francisco, CA, US
1120 Veterans Blvd
Tampa, FL, US
2202 N Westshore Blvd
Washington, DC, US
601 13th St NW 12th Floor
Show all (66)

Amgen Financials and Metrics

Amgen Revenue

Embed Graph
View revenue for all periods
Amgen's revenue was reported to be $25.42 b in FY, 2020 which is a 8.8% increase from the previous period.
USD

Revenue (Q2, 2021)

6.5b

Gross profit (Q2, 2021)

4.9b

Gross profit margin (Q2, 2021), %

74.9%

Net income (Q2, 2021)

464.0m

EBIT (Q2, 2021)

828.0m

Market capitalization (14-Sept-2021)

124.1b

Closing stock price (14-Sept-2021)

216.0

Cash (30-Jun-2021)

6.6b

EV

150.3b
Amgen's current market capitalization is $124.1 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

23.7b23.4b25.4b

Revenue growth, %

4%(2%)9%

Cost of goods sold

4.1b4.4b6.2b

Gross profit

19.6b19.0b19.3b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

5.6b5.9b5.7b6.2b6.2b6.4b5.9b6.5b

Cost of goods sold

1.1b1.0b1.0b1.5b1.5b1.6b1.5b1.6b

Gross profit

4.5b4.9b4.7b4.6b4.7b4.9b4.4b4.9b

Gross profit Margin, %

81%83%82%75%76%76%75%75%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

6.9b6.0b6.3b

Accounts Receivable

3.6b4.1b4.5b

Inventories

2.9b3.6b3.9b

Current Assets

37.6b18.4b21.1b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

7.4b5.5b11.4b7.7b9.1b9.1b6.1b6.6b

Accounts Receivable

3.8b3.8b3.6b5.0b5.4b4.1b4.4b4.5b

Inventories

3.0b3.2b3.2b3.7b3.8b3.9b4.0b4.1b

Current Assets

35.2b30.7b31.1b18.8b22.9b22.7b21.3b19.1b
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

8.4b7.8b7.3b

Depreciation and Amortization

1.9b2.2b3.6b

Inventories

(3.0m)(66.0m)(215.0m)

Accounts Payable

(143.0m)164.0m45.0m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

2.0b4.2b6.1b1.8b3.6b5.6b1.6b2.1b

Depreciation and Amortization

495.0m996.0m1.5b897.0m1.8b2.7b841.0m1.7b

Inventories

(28.0m)(118.0m)(101.0m)(113.0m)(226.0m)(316.0m)(126.0m)(167.0m)

Accounts Payable

(112.0m)(205.0m)(196.0m)(25.0m)(216.0m)(202.0m)(29.0m)(156.0m)
USDFY, 2018

EV/EBIT

14.6 x

EV/CFO

13.2 x

Revenue/Employee

1.1m

Debt/Equity

2.7 x

Debt/Assets

0.5 x

Financial Leverage

5.3 x

P/E Ratio

15.4
Show all financial metrics

Amgen Operating Metrics

FY, 2018FY, 2019FY, 2020

Countries

100100100

Facilities

190190180

Patents (US)

273431

Phase III Trials Products

71011
Show all operating metrics

Amgen Acquisitions / Subsidiaries

Company NameDateDeal Size
Five Prime TherapeuticsApril 16, 2021$1.9 b
Rodeo TherapeuticsMarch 31, 2021$55 m
OtezlaNovember 19, 2019$13.4 b
NuevolutionMay 22, 2019
CatherexDecember 21, 2015
Dezima PharmaSeptember 16, 2015$300 m
Onyx PharmaceuticalsAugust 24, 2013$10.5 b
DeCODE GeneticsDecember 10, 2012$415 m
MN PharmaceuticalsApril 26, 2012$700 m
KAI PharmaceuticalsApril 10, 2012$315 m
Show more

Amgen Revenue Breakdown

Embed Graph

Amgen revenue breakdown by business segment: 8.6% from Otezla, 19.7% from Enbrel, 9.0% from Neulasta, 10.9% from Prolia, 7.5% from XGEVA, 6.2% from Aranesp, 25.9% from Other Products and 12.3% from Other

Amgen revenue breakdown by geographic segment: 72.8% from United States and 27.2% from Rest of World

Show all human capital metrics

Amgen Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Amgen Online and Social Media Presence

Embed Graph

Amgen Company Culture

  • Overall Culture

    F

    43/100

  • CEO Rating

    F

    55/100

  • Compensation

    F

    10/100

Learn more on Comparably

Amgen News and Updates

Amgen To Present At The 2021 Bank of America Merrill Lynch Global Healthcare Conference

THOUSAND OAKS, Calif., Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:45 a.m. ET on Friday, Sept. 17, 2021. Peter H. Griffith, executive vice president and chief financial officer at Amgen will...

Amgen To Webcast Investor Call At ESMO 2021

THOUSAND OAKS, Calif., Sept. 13, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2021 Congress. On Thursday, Sept. 16, 2021, at 8:30 a.m. ET, David M. Reese, M.D., executive...

Insights on the Anti-Tumor Drugs Global Market to 2026 - Featuring Amgen, Astellas Pharma and Bayer Among Others

Dublin, Sept. 13, 2021 (GLOBE NEWSWIRE) -- The "Anti-Tumor Drugs Market Research Report by Indications, by Drug Class, by End User, by Route of Administration, by Distribution Channels, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets…

UK’s MHRA approves Amgen’s sotorasib for non-small cell lung cancer

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen's sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation.

Green light for Amgen KRAS inhibitor in the united kingdom

Green light for Amgen KRAS inhibitor in the united kingdom

3M , Amgen Inc . share losses lead Dow 211 - point fall

3M , Amgen Inc . share losses lead Dow 211 - point fall
Show more

Amgen Frequently Asked Questions

  • When was Amgen founded?

    Amgen was founded in 1980.

  • Who are Amgen key executives?

    Amgen's key executives are Robert A. Bradway, Victoria H. Blatter and Judy Gawlik Brown.

  • How many employees does Amgen have?

    Amgen has 24,300 employees.

  • What is Amgen revenue?

    Latest Amgen annual revenue is $25.4 b.

  • What is Amgen revenue per employee?

    Latest Amgen revenue per employee is $1 m.

  • Who are Amgen competitors?

    Competitors of Amgen include PRA Health Sciences, Viatris and Allergan.

  • Where is Amgen headquarters?

    Amgen headquarters is located at 1 Amgen Center Dr, Thousand Oaks.

  • Where are Amgen offices?

    Amgen has offices in Thousand Oaks, Cambridge, Louisville, South San Francisco and in 58 other locations.

  • How many offices does Amgen have?

    Amgen has 66 offices.